P3 Health Partners Stock Current Valuation
| PIII Stock | USD 0.18 0.0004 0.22% |
Valuation analysis of P3 Health Partners helps investors to measure P3 Health's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The P3 Health's current Enterprise Value is estimated to increase to about 398.5 M, while Enterprise Value Over EBITDA is projected to decrease to (2.45). Fundamental drivers impacting P3 Health's valuation include:
Overvalued
Today
Please note that P3 Health's price fluctuation is out of control at this time. Calculation of the real value of P3 Health Partners is based on 3 months time horizon. Increasing P3 Health's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since P3 Health is currently traded on the exchange, buyers and sellers on that exchange determine the market value of PIII Stock. However, P3 Health's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.18 | Real 0.17 | Target 0.63 | Hype 0.18 | Naive 0.17 |
The intrinsic value of P3 Health's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence P3 Health's stock price.
Estimating the potential upside or downside of P3 Health Partners helps investors to forecast how PIII stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of P3 Health more accurately as focusing exclusively on P3 Health's fundamentals will not take into account other important factors: P3 Health Partners Company Current Valuation Analysis
P3 Health's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current P3 Health Current Valuation | 112.97 M |
Most of P3 Health's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, P3 Health Partners is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
PIII Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for P3 Health is extremely important. It helps to project a fair market value of PIII Stock properly, considering its historical fundamentals such as Current Valuation. Since P3 Health's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of P3 Health's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of P3 Health's interrelated accounts and indicators.
Click cells to compare fundamentals
PIII Current Valuation Historical Pattern
Today, most investors in P3 Health Stock are looking for potential investment opportunities by analyzing not only static indicators but also various P3 Health's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of P3 Health current valuation as a starting point in their analysis.
P3 Health Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, P3 Health Partners has a Current Valuation of 112.97 M. This is 99.21% lower than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 99.32% higher than that of the company.
PIII Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses P3 Health's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of P3 Health could also be used in its relative valuation, which is a method of valuing P3 Health by comparing valuation metrics of similar companies.P3 Health is currently under evaluation in current valuation category among its peers.
PIII Fundamentals
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 112.97 M | ||||
| Shares Outstanding | 162.86 M | ||||
| Shares Owned By Insiders | 23.20 % | ||||
| Shares Owned By Institutions | 24.98 % | ||||
| Number Of Shares Shorted | 4.38 M | ||||
| Price To Book | 0.26 X | ||||
| Price To Sales | 0.07 X | ||||
| Revenue | 1.27 B | ||||
| Gross Profit | 8.73 M | ||||
| EBITDA | (81.07 M) | ||||
| Net Income | (57.77 M) | ||||
| Cash And Equivalents | 63.15 M | ||||
| Cash Per Share | 1.52 X | ||||
| Total Debt | 121.94 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 0.75 X | ||||
| Book Value Per Share | 1.22 X | ||||
| Cash Flow From Operations | (76.03 M) | ||||
| Short Ratio | 1.21 X | ||||
| Earnings Per Share | (0.86) X | ||||
| Target Price | 0.63 | ||||
| Number Of Employees | 400 | ||||
| Beta | 1.14 | ||||
| Market Capitalization | 97.19 M | ||||
| Total Asset | 860.97 M | ||||
| Retained Earnings | (367.34 M) | ||||
| Working Capital | (133.35 M) | ||||
| Net Asset | 860.97 M |
About P3 Health Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze P3 Health Partners's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of P3 Health using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of P3 Health Partners based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Check out P3 Health Piotroski F Score and P3 Health Altman Z Score analysis. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of P3 Health. If investors know PIII will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about P3 Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.86) | Revenue Per Share | Quarterly Revenue Growth 0.152 | Return On Assets | Return On Equity |
The market value of P3 Health Partners is measured differently than its book value, which is the value of PIII that is recorded on the company's balance sheet. Investors also form their own opinion of P3 Health's value that differs from its market value or its book value, called intrinsic value, which is P3 Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because P3 Health's market value can be influenced by many factors that don't directly affect P3 Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between P3 Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if P3 Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, P3 Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.